Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03431168 · ClinicalTrials.gov registry record · Phase 2
A Novel Regimen to Prevent Malaria and STI in Pregnant Women With HIV
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 308
- Enrollment target
NCT03431168 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 308 participants.
The verdict
NCT03431168, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 308 participants
- Enrollment target
Study Summary
More than 3 billion people worldwide are at risk of acquiring malaria and pregnant women living with HIV in Africa are at particular risk. An effective prophylaxis regimen capable of preventing malaria and other common perinatal infections would have great potential to improve adverse birth outcomes. The purpose of this randomized controlled trial is to evaluate a new combination prophylaxis regimen in pregnant women with HIV in Cameroon to determine its efficacy and safety.
Interventions
- DRUG Azithromycin/TMPS
- DRUG Placebo/TMPS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 308 participants |
| Start Date | 2018-03-07 |
| Est. Completion | 2022-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03431168
The ClinicalTrials.gov registry entry for NCT03431168 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 308 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Azithromycin/TMPS is the first listed.
NCT03431168 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03431168 about?
NCT03431168 is a clinical study titled "A Novel Regimen to Prevent Malaria and STI in Pregnant Women With HIV". More than 3 billion people worldwide are at risk of acquiring malaria and pregnant women living with HIV in Africa are at particular risk. An effective prophylaxis regimen capable of preventing malaria and other common perinatal infections would have great potential to improve adverse birth outcomes...
What is the current status of trial NCT03431168?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 308 participants. The study started on 2018-03-07. Estimated completion is 2022-01-01.
What interventions are being tested in trial NCT03431168?
The interventions under investigation include: Azithromycin/TMPS (DRUG), Placebo/TMPS (DRUG).
Who is sponsoring clinical trial NCT03431168?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.